Nanjing Chia-Tai Tianqing Pharmaceutical
Clinical trials sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical, explained in plain language.
A Chinese pharmaceutical company developing and commercializing drugs, a subsidiary of CTTQ.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could replace infusions for rare blood disorder Results expected Nov 2026 (estimated)
- New drug NTB003 aims to reduce bulging eyes in thyroid disease Results expected May 2027 (estimated)
-
New pill aims to tame rare blood disorder PNH
Disease control OngoingThis Phase 2 trial tests NTQ5082, an oral drug, in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where red blood cells break apart. The drug blocks a part of the immune system to prevent this destruction. The main goal is to see if it can raise h…
Phase 2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug NTB003 enters first human safety tests
Knowledge-focused By invitation onlyThis Phase 1 trial is testing a new drug called NTB003 in 40 healthy adults to see if it is safe and how the body processes it. Participants will receive either NTB003 or a placebo in increasing doses. The study is an early step toward possibly treating thyroid eye disease, but i…
Phase 1 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:57 UTC